



BD

Advancing the world of health™

Q1 FY21 Financial results



Creating value through fulfilling our purpose

"BD's strong revenue and EPS growth reflect solid execution across the company and positive momentum to start fiscal 2021," said Tom Polen, CEO and president of BD. "While the market continues to be dynamic with the COVID-19 pandemic, BD has emerged as an essential partner to help the world respond to the COVID-19 pandemic from diagnostics to devices used in treatment to injection devices for vaccines and real-time surveillance and reporting. I'm proud of the worldwide BD team for their COVID-19 response efforts and support of healthcare providers around the world. We are focused on driving our BD 2025 Grow-Simplify-Empower strategic initiatives which include bringing new and exciting innovations to the health care markets, expanding access globally and creating value for our shareholders. To that end, we continue to make solid progress."

—Tom Polen, CEO and President

BD earned a perfect score on the Human Rights Campaign Corporate Equality Index for the

4th

consecutive year



BD recognized for gender equality by Bloomberg for the

2nd

year in a row



Q1 FY21 financials

FXN revenue growth¹ of

24.3%

Adjusted EPS² of

\$4.55

Our innovation, scale and execution enable us to be an essential partner in responding to the global COVID-19 pandemic



Nearly tripling³ our BD Veritor™ Systems to

>70,000

Commitments for over

1B

injection devices to enable COVID-19 vaccinations⁴

Resilience of the core business

Acuity, demand for critical need products, and procedure resiliency drove revenue growth

BD Medical FXN revenue growth¹

6.9%

BD Interventional FXN revenue growth¹

5.0%

Our climate change targets: Commitment to reduce Scope 1 and 2 GHG emissions

46%

by 2030 (from a 2019 baseline) and to be

carbon neutral

across direct operations by 2040. This science-based target is aligned with a

1.5°C

global emissions reduction pathway.



1. Reflects currency-neutral revenue growth for the three-month period ended December 31, 2020 compared to the comparable period in 2019 on a year-over-year basis.
2. Reflects adjusted non-GAAP earnings per share, which excludes, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, restructuring and transaction costs.
3. Represents the number of BD Veritor™ analyzers added since the beginning of the COVID-19 pandemic.
4. As of December 2020.

These materials include non-GAAP financial measures. A reconciliation to the comparable GAAP measures can be found in our earnings release including the financial schedules and financial supplements, posted on the "Investors" section of the BD.com website. This document contains forward-looking statements and it's possible that actual results could differ from our expectations. Factors that could cause such differences appear in our first quarter of fiscal 2021 earnings release furnished as an exhibit to the Form 8-K that BD filed on February 4, 2021 with the SEC, and in our recent SEC filings.

